Carimune

Product NDC: 44206-418
11-digit product format: 442060418
Labeler code: 44206
Product ID: 44206-418_6d78337d-6fba-4156-a522-1c03c9181489
Type: PLASMA DERIVATIVE
Nonproprietary name: HUMAN IMMUNOGLOBULIN G
Dosage form: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Route: INTRAVENOUS
Labeler: CSL Behring AG
Application: BLA102367
Marketing category: BLA
Marketing start: 2009-02-10
Marketing end: 2021-05-31
Substance: HUMAN IMMUNOGLOBULIN G
Active strength: 12 g/1
Pharmacologic classes: Human Immunoglobulin G [EPC],Passively Acquired Immunity [PE],Antigen Neutralization [MoA],Immunoglobulins [CS]
NDC exclude flag: No
Listing certified through: 0000-00-00
Current FDA listing: Historical FDA.report record

NDC auxiliary status#

Explicit status records from FDA unfinished, excluded, and compounder auxiliary files. Absence of a row is not itself a regulatory status. Browse every current auxiliary row, including rows without a usable NDC. · Browse every captured source and parsed snapshot.

Current NDC status page 1 of 1 · 2 matching rows.

Dataset, Scope, Product NDC table
Dataset	Scope	Product NDC	Package NDC	Code	Status	Reporting period	Source date
excluded product	product	44206-418		D	Discontinued by firm		2026-07-31
excluded package	package	44206-418	44206-418-12	D	Discontinued by firm		2026-07-31

Package NDC, Billing unit, Product NDC table
Package NDC	Billing unit	Product NDC	DailyMed indexing SPL	SPL version	Effective
44206-418-12	EA - Each	44206-418	88eb182a-7051-4b3d-a51e-f2991e50b7b5	1	2012-07-24
44206-418-92	EA - Each	44206-418	bf7d5087-8e2f-4575-91bc-183068ec76d4	1	2017-03-06

Ingredient, Type, UNII table
Ingredient	Type	UNII	DailyMed label	SPL version
HUMAN IMMUNOGLOBULIN G	ACTIVE INGREDIENT	66Y330CJHS	CARIMUNE NANOFILTERED (HUMAN IMMUNOGLOBULIN G) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [CSL BEHRING AG]	8
HUMAN IMMUNOGLOBULIN G	ACTIVE MOIETY	66Y330CJHS	CARIMUNE NANOFILTERED (HUMAN IMMUNOGLOBULIN G) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [CSL BEHRING AG]	8
Sodium Chloride	INACTIVE INGREDIENT	451W47IQ8X	CARIMUNE NANOFILTERED (HUMAN IMMUNOGLOBULIN G) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [CSL BEHRING AG]	8
Sucrose	INACTIVE INGREDIENT	C151H8M554	CARIMUNE NANOFILTERED (HUMAN IMMUNOGLOBULIN G) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [CSL BEHRING AG]	8

BLA, Proprietary name, Proper name table
BLA	Proprietary name	Proper name	License type	Status	Latest source
102367	Carimune, Carimune Nf, Panglobulin, Sandoglobulin	Immune Globulin Intravenous (Human)	351(a)	Disc	2026-06-01

UNII, Preferred term, Registry number table
UNII	Preferred term	Registry number	Matched term
66Y330CJHS	HUMAN IMMUNOGLOBULIN G	308067-58-5	HUMAN IMMUNOGLOBULIN G

Package NDC, 11-digit format, Description table
Package NDC	11-digit format	Description	Marketing start	Marketing end	Sample	Exclude flag	Status
44206-418-12	44206041812	1 VIAL, SINGLE-USE in 1 CARTON (44206-418-12) > 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-USE (44206-418-92)	2009-02-10	2021-05-31	No	No	Current

Title, Manufacturer, Effective date table
Title	Manufacturer	Effective date	Type	Version
Immune Globulin Intravenous (Human) Carimune ® NF, Nanofiltered	CSL Behring AG	2020-02-10	PLASMA DERIVATIVE	13